You are here

U.S. Joins Whistleblower Case Against Insys Over Kickbacks

Six states will also participate in the litigation

The Department of Justice has joined whistleblower litigation accusing Insys Therapeutics, Inc., of trying to generate more profit by paying kickbacks to doctors to prescribe powerful opioid medications, Reuters reports.

The government’s involvement was disclosed in a filing made public earlier this week. It adds firepower to the civil litigation as Insys tries to resolve a federal probe into its marketing of Subsys, a spray formulation of fentanyl.

Six U.S. states—California, Colorado, Indiana, New York, North Carolina and Virginia—also joined whistleblower litigation against Insys, according to the filing in U.S. District Court in Los Angeles.

The litigation comes amid a wave of related criminal cases against medical practitioners, and former executives and sales representatives employed by Insys, including its billionaire founder John Kapoor.

In a separate filing, the Justice Department asked that the litigation be put on hold until the criminal cases were resolved.

Chandler, Arizona-based Insys had no immediate comment. Its shares closed up 7.6% at $7.36 on the Nasdaq.

Subsys is an under-the-tongue spray approved to treat severe pain in cancer patients who are already receiving and tolerant to around-the-clock opioid therapy.

The U.S. government accused Insys of having since 2012 offered “sham” speaking fees and lavish meals to induce doctors to prescribe Subsys.

It also said Insys knowingly caused Medicare and other federal health care programs to pay for Subsys by encouraging doctors to prescribe it when it was not medically necessary, or by misrepresenting patients’ diagnoses.

Opioids, including prescription painkillers and heroin, played a role in a record 42,249 U.S. deaths in 2016, according to the Centers for Disease Control and Prevention.

In March, President Donald Trump called for litigation against companies over their roles in what he has called a nationwide epidemic.

Federal prosecutors in Boston have said Kapoor and six other former Insys executives and managers schemed to bribe doctors to prescribe Subsys and to defraud insurers into paying for it.

Insys has estimated it might cost at least $150 million to resolve the Justice Department probe.

The litigation that the U.S. government joined included a 2013 lawsuit by Maria Guzman, a former Insys sales representative who said doctors improperly prescribed Subsys for off-label uses such as treating back pain.

She sued under the False Claims Act, which lets private whistleblowers sue on the government’s behalf and share in recoveries.

Source: Reuters; May 14, 2018.

More Headlines

COMPASS Trial Shows 24% Reduction in Major CV Events
Only 18.7% of Patients Treated Had Uveitis Recurrence
Protein Organizes and Stores DNA for B Cells in Methodical Fashion
Patients’ Bodies Most Common Source of Hospital-Acquired Bloodstream Infections
Growing opioid crisis fueling suicide increase according to study
Vaccine Prevents Some Cancers, Diseases Caused by 9 HPV Types
In Future, Providers May Screen for APOE4 Before Treatment 
MIT Professor Working to Produce Thousands of Drugs on Demand
Agency Scrutinizes Attempts to Block Generics